Publication
Road to COP29: Our insights
The 28th Conference of the Parties on Climate Change (COP28) took place on November 30 - December 12 in Dubai.
Navigating Brexit, and beyond
With the UK and the wider EU facing the consequences of Brexit, financial services firms globally need to ensure that they understand the impact of Brexit on their business so they can manage the challenges and pursue the opportunities.
We have created the Brexit Pathfinder hub on our NRF Institute to help financial services clients navigate the legal and regulatory implications of Brexit. The hub includes our latest views and analysis on regulatory issues, as well as access to our UK Statutory Instrument tracker.
Also available via the hub is PathfinderPLUS, a subscription-only service providing clients with access to additional, exclusive materials including consolidated versions of the onshore UK legislation.
For Brexit advice, please contact your usual Norton Rose Fulbright contact or one of our core Financial Services Brexit team members below.
Register for the hub
To request access to ‘Brexit Pathfinder’, please register to join NRF Institute.
Registration indicates acceptance of the terms and conditions which include important information about how our product will be delivered.
Members of NRF Institute can access a range of premium content including knowledge hubs and cross-border guides.
Recent publications
Publication
Country risk in unprecedented times: A precedent for cross-border loan documentation?
While country risk cannot be avoided in cross-border transactions entirely, it can be effectively mitigated through careful transaction structuring and tailored contractual protections.
Publication
The GCR Guide to Life Sciences – Merger control: Procedural issues
Miranda Cole, Julien Haverals and Emma Clarke of our Brussels/ London offices are the authors of a chapter on procedural issues in merger control that has been published in the third edition of the Global Competition Review’s The Guide to Life Sciences. This covers a number of significant procedural developments that have affected merger review of life sciences transactions.
Subscribe and stay up to date with the latest legal news, information and events . . .